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Lamivudine (3TC), a drug used in the treatment of HIV infection, needs to cross the
plasma membrane to exert its therapeutic action. Human Organic cation transporter 1
(hOCT1), encoded by the SLC22A1 gene, is the transporter responsible for its uptake
into target cells. As SLC22A1 is a highly polymorphic gene, the aim of this study was
to determine how SNPs in the OCT1-encoding gene affected 3TC internalization and its
interaction with other co-administered drugs. HEK293 cells stably transfected with either
the wild type form or the polymorphic variants of hOCT1 were used to perform kinetic
and drug-drug interaction studies. Protein co-immunoprecipitation was used to assess
the impact of selected polymorphic cysteines on the oligomerization of the transporter.
Results showed that 3TC transport efficiency was reduced in all polymorphic variants
tested (R61C, C88R, S189L, M420del, and G465R). This was not caused by lack of
oligomerization in case of variants located at the transporter extracellular loop (R61C
and C88R). Drug-drug interaction measurements showed that co-administered drugs
[abacavir (ABC), zidovudine (AZT), emtricitabine (FTC), tenofovir diproxil fumarate (TDF),
efavirenz (EFV) and raltegravir (RAL)], differently inhibited 3TC uptake depending upon
the polymorphic variant analyzed. These data highlight the need for accurate analysis of
drug transporter polymorphic variants of clinical relevance, because polymorphisms can
impact on substrate (3TC) translocation but even more importantly they can differentially
affect drug-drug interactions at the transporter level.
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INTRODUCTION
The human Organic Cation Transporter 1 (hOCT1), encoded
by the SLC22A1 gene, is a plasma membrane transporter
protein responsible for the translocation of a broad range of
drugs currently used, among others, in anti-diabetic, antiemetic,
antihypertensive, anticancer and antiviral therapies (Koepsell
et al., 2007; Nies et al., 2011; Arimany-Nardi et al., 2015a).
hOCT1 is expressed in major epithelial barriers thereby being
a suitable candidate to determine drug bioavailability and
action (Tzvetkov et al., 2009; Nies et al., 2011). The synthesis
of fully active hOCT1 proteins requires the formation of
homo-oligomers. Cysteines located at the extracellular loop
between transmembrane domains (TMD) 1 and 2 are known
to be implicated in the oligomerization of hOCT1 by forming
di-sulphide bonds (Keller et al., 2011).
Moreover, SLC22A1 is a highly polymorphic gene with many
of its polymorphic variants present in a high percentage of
the population (Kerb et al., 2002; Shu et al., 2003; Arimany-
Nardi et al., 2015a). Some of these polymorphic variants lead
to amino acid substitutions and, at least in one case, can even
induce deletions, as for the M420del variant. In most cases these
hOCT1 polymorphic variants have been shown to significantly
alter the capacity of the transporter to translocate its substrates in
a manner which can differentially affect substrate specificity. In
fact, a paradigm in the field of drug transporter pharmacogenetics
is the cellular handling of metformin by hOCT1, its polymorphic
variants being responsible for a variety of pharmacokinetics and
pharmacodynamics effects (Ahlin et al., 2011).
The antiviral drug lamivudine (3TC) has also been shown
to be a suitable hOCT1 substrate (Minuesa et al., 2009).
Interestingly, two rare variants found in Asian population have
been shown to alter 3TC uptake by hOCT1 (Jung et al.,
2008; Choi and Song, 2012). 3TC is a broadly used drug for
the treatment of Human Immunodeficiency Virus (HIV) and
Hepatitis B virus (HBV) infections. High doses of the drug are
used in monotherapy for the treatment of HBV infection, while
low drug doses are used in combination with other antiretroviral
agents (mostly, abacavir -ABC- and azidothymidine -AZT-) for
the treatment of HIV infection (Johnson et al., 1999). Moreover,
several of these antiretroviral drugs, which are being used in
combination for the treatment of HIV infection, have been also
shown to interact with hOCT proteins (Jung et al., 2008; Minuesa
et al., 2009). However, this interaction might be mechanistically
complex as they can bind with high affinity to the transporter
allosterically inhibiting substrate translocation, without being
transported themselves. Essentially, high affinity binding of other
antiviral nucleosides might result in inhibition of 3TC uptake,
Abbreviations: hOCT, Human organic cation transporter; 3TC, lamivudine; WT,
wild type; TMD, transmembrane domain; HIV, Human Immunodeficiency Virus;
HBV, Hepatitis B virus; ABC, abacavir; AZT, azidothymidine; AIDS, acquired
immune deficiency syndrome; MDMs, Monocyte-DerivedMacrophages; MDDCs,
Monocyte-Derived Dendritic Cells; PBMCs, Peripheral Blood Mononuclear
Cells; MPP+, N-Methyl-4-phenyl pyridinium iodide; FTC, emtricitabine; TDF,
tenofovir diproxil fumarate; EFV, efavirenz; RAL, raltegravir; HEK, Human
embrionic kidney; NRTI- Nucleoside Reverse Transcriptase Inhibitors; NNRTI,
Non-Nucleoside Reverse Transcriptase Inhibitor.
thereby anticipating the occurrence of drug-drug interactions at
the transporter level in AIDS therapy (Minuesa et al., 2009).
hOCT1 is highly expressed in hepatocytes, being a good
candidate to play a major role in the efficacy of 3TC treatment
of HBV infection (Nies et al., 2009). Interestingly enough,
hOCT expression has also been detected in immune cells.
Both hOCT1 and hOCT3 have been shown to be expressed
in monocytes, Monocyte-Derived Macrophages (MDMs) and
Monocyte-Derived Dendritic Cells (MDDCs) and also in
Peripheral Blood Mononuclear Cells (PBMCs) and CD4+ T cells
(Minuesa et al., 2008). In fact, hOCT1 together with hOCT2
have also been reported to be responsible for the accumulation
of 3TC in CD4+ cells of HIV-infected patients (Jung et al.,
2013). Moreover, hOCT1 mRNA expression has been shown to
be increased in the lymph nodes of HIV-infected patients in
comparison to healthy controls (Jung et al., 2008).
How hOCT1 genetic heterogeneity might affect 3TC-
transporter interaction and, more importantly, how hOCT1
polymorphisms might determine drug-drug interactions at
the transporter level, has not been studied so far. In this
study, we have undertaken the analysis of the ability of
hOCT1 polymorphic variants to interact and translocate 3TC,
and how this interaction can be affected by the presence
of other antiretroviral drugs currently used in the clinics.
Considering that two of the described hOCT1 polymorphic
variants (hOCT1R61C and hOCT1C88R) implicate cysteine
residues, which are known to be located at the extracellular loop
between TMDs 1 and 2, the impact of these two variants on
the ability of the hOCT1 protein to oligomerize has also been
assessed in order to unveil any structural constraints associated
with these genetic variants.
MATERIALS AND METHODS
Reagents
N-Methyl-4-phenyl pyridinium iodide (MPP+) and lamivudine
(3TC) were obtained from Sigma-Aldrich (St. Louis, MO).
Abacavir (ABC), zidovudine (AZT), emtricitabine (FTC),
tenofovir diproxil fumarate (TDF), efavirenz (EFV) and
raltegravir (RAL) were obtained from the NIH AIDS Research
and Reference Reagent Program. [Methyl-3H]-N-Methyl-4-
phenyl pyridinium iodide ([3H]MPP+) was obtained from
American Radiolabeled Chemicals, Inc. (St. Louis, MO), [5-
3H(N)]lamivudine ([3H]3TC) was purchased at, Hartmann
Analytic GmbH (Braunschweig, Germany).
Molecular Biology
The polymorphic substitutions in hOCT1 (GenBank accession
number X98322) (Gorboulev et al., 1997) were introduced using
the primers shown in Table 1. The constructs generated were
verified by DNA sequencing (BigDye Terminator v3.1, Applied
Biosystems, Foster City, CA).
For generating the stable expressing cell lines, hOCT1,
hOCT1R61C, hOCT1C88R, hOCT1S189L, hOCT1M420Del
or hOCT1G465R were recloned into the pcDNA5/FRT/TO
vector (Invitrogen, Carlsbad, CA). Restriction sites were added
using the following primers (restriction sites underlined): 5′-
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TABLE 1 | Primers (5′-3′) used to introduce the polymorphic variations
into hOCT1.
R61C Fw CTGGGGTGGCTGAGCTGAGCCAGTGCTGTGGCTGGAG
CCCTGCGGAGG
Rv CCTCCGCAGGGCTCCAGCCACAGCACTGGCTCAGCTC
AGCCACCCCAG
C88R Fw GGGCGAGGCCTTCCTTGGCCAGCGCAGGCGCTATGAAG
TGGACTGG
Rv CCAGTCCACTTCATAGCGCCTGCGCTGGCCAAGGAAGGC
CTCGCCC
F160L Fw GTCCTGTTTGAATGCGGGCTTCCTCTTTGGCTCTCTCG
GTGTTGGC
Rv GCCAACACCGAGAGAGCCAAAGAGGAAGCCCGCATTCAA
ACAGGAC
S189L Fw GAACTGTGCTGGTCAACGCGGTGTTGGGCGTGCTCATG
GCCTTCTCGCC
Rv GGCGAGAAGGCCATGAGCACGCCCAACACCGCGTTG
ACCAGCACAGTTC
P341L Fw CATTTGCAGACCTGTTCCGCACGCTGCGCCTGAGGAA
GCGCACCTTC
Rv GAAGGTGCGCTTCCTCAGGCGCAGCGTGCGGAACAGGT
CTGCAAATG
G401S Fw CCCTCATCACCATTGACCGCGTGAGCCGCATCTACCCCA
TGGCCATGTC
Rv GACATGGCCATGGGGTAGATGCGGCTCACGCGGTCAAT
GGTGATGAGGG
M408V Fw GGGCCGCATCTACCCCATGGCCGTGTCAAATTTGTTGG
CGGGGGCAG
Rv CTGCCCCCGCCAACAAATTTGACACGGCCATGGGGTA
GATGCGGCCC
M420Del Fw GGCGGGGGCAGCCTGCCTCGTCATTTTTATCTCACCTG
ACCTGC
Rv GCAGGTCAGGTGAGATAAAAATGACGAGGCAGGCTGCC
CCCGCC
G465R Fw CCCCACATTCGTCAGGAACCTCCGAGTGATGGTGTGTTCC
TCCCTG
Rv CAGGGAGGAACACACCATCACTCGGAGGTTCCTGACG
AATGTGGGG
The variations introduced have been underlined in forward (Fw) and reverse (Rv) primers.
CGGGGTACCATCATGCCCACCGTGGATGACA -3′ and 5′-
CGCGGATCCCTCTCAGGTGCCCGAGGGTTC -3′ and the
amplification product was subcloned into KpnI and BamHI sites
of pcDNA5/FRT/TO vector.
Cell Culture
Human embryonic kidney 293 cells (HEK293) were routinely
maintained at 37◦C/5% CO2 in Dulbecco’s modified
Eagle’s medium (Lonza Verviers SPRL, Verviers, Belgium)
supplemented with 10% heat-inactivated fetal bovine serum
(vol/vol), 2 mM glutamine, and a mixture of antibiotics (100 U
penicillin, 0.1 mg/ml streptomycin, and 0.25 mg/ml fungizone)
(Life Technologies, Paisley, UK).
FlpIn-HEK293 cells were maintained in the same medium
supplemented with 100 µg/ml hygromycin B (Life Technologies,
Paisley, UK).
Transfection of hOCTs in HEK293 Cells and
Cell Culture
HEK293 cells were transiently transfected using calcium
phosphate.
To generate the stable cell lines the eukaryotic expression
vectors and an empty vector (pcDNA5), used as a control in
uptake experiments, were transfected into the FlpIn-HEK293 cell
line (Life Technologies, Paisley, UK) using calcium-phosphate
and selected for positive clones with 100 µg/ml hygromycin B
(Life Technologies, Paisley, UK).
Cell clones with the highest transport activity were chosen
for further study. They were routinely cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Lonza Verviers SPRL,
Verviers, Belgium) supplemented with 10% heat-inactivated fetal
bovine serum (v/v), 2 mM glutamine, and amixture of antibiotics
(100 U penicillin, 0.1 mg/ml streptomycin, and 0.25 mg/ml
fungizone) (Life Technologies, Paisley, UK) in the presence of
100 µg/ml hygromycin B. They were maintained at 37◦C in a
humidified atmosphere containing 5% CO2.
Uptake Measurements
[3H]MPP+ and [3H]3TC uptake in HEK293-hOCTs and/or
HEK293-pcDNA5 (empty vector) cells was measured after 1 s
(MPP+) and 15 s (3TC) incubations as previously described
(Minuesa et al., 2009).
For kinetics studies increasing concentrations of the non-
labeled drug were used and the obtained values were fitted
into a Michaelis-Menten curve to calculate the Km and Vmax
values.
Co-Precipitation of His-Tagged and
FLAG-Tagged Transporters
Target proteins were cell free expressed as previously reported
(Keller et al., 2011). The precipitates of the target proteins
were then solubilized in Tris buffer containing 2% 1-myristoyl-
2-hydroxy-snglycero-3-[phospho-rac-(1-glycerol)](LMPG),
followed by centrifugation for 10 min at 13,000 g. To investigate
protein-protein interactions LMPG supernatant (100 µL with
20 µg of protein) containing one in vitro-expressed transporter
with a His tag was mixed with LMPG supernatant (100 µL
with 20 µg of protein) containing an in vitro-expressed FLAG-
tagged transporter and diluted with 200 µL of Tris buffer
containing 1% CHAPS and 10 mM imidazole (final detergent
concentrations, 1% LMPG and 0.5% CHAPS) and incubated
for 1 h at 4◦C; 100 µL of Ni2+-NTA-agarose equilibrated
with Tris buffer containing 1% LMPG, 0.5% CHAPS, and 10
mM imidazole was added and the suspension incubated for
an additional 1 h at 4◦C, and the beads were separated via
centrifugation for 10 min at 500 g (room temperature). The
beads were washed five times at room temperature with 1 mL
of Tris buffer containing 1% CHAPS and 10 mM imidazole-
CHAPS and five times with Tris buffer containing 1% CHAPS
and 20 mM imidazole. For protein elution, pelleted beads
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were suspended for 10 min at room temperature in 400 µL
of Tris buffer containing 1% CHAPS and 100 mM imidazole,
and the suspension was centrifuged for 10 min at 500 g. The
supernatants were collected, and FLAG-tagged transporters were
analyzed by Western blots as previously described (Keller et al.,
2011).
Statistical Analysis
Paired and unpaired t-Student test were carried out using
GraphPad Prism 4.0 software for the statistical comparison of
experimental data.
RESULTS
Effect of hOCT1 Polymorphisms in
Lamivudine, Metformin and MPP+ Uptake
The impact of hOCT1 polymorphic variants on the uptake
of 3TC was assessed. For this purpose, the most common
polymorphic variants of the SLC22A1 gene were generated by
site-directed mutagenesis of the reference (wild type) cDNA
template and transiently transfected with these vectors in HeLa
cells. The uptake rates of 10 µM [3H]3TC and 1 µM [3H]MPP+
by these transporter variants were measured and compared
to the ones for metformin published by Shu et al. (2007)
(Supplementary Figure 1). Transport activities expressed as the
percentages of total wild type-associated transport are shown in
Table 2.
Interestingly, polymorphic variants did not similarly affect
the uptake of all drugs, being the most striking differences in
substrate selectivity those found in variants R61C, S189L, and
M420del. Those polymorphisms combining both a relatively high
allelic frequency in humans, and substrate-dependent altered
transport function (variants R61C, C88R, S189L, M420del,
and G465R; highlighted in Table 2) as well as the wild type
hOCT1 were chosen to generate a panel of HEK293 cell lines,
stably expressing each single polymorphic hOCT1 protein.
This panel of cell lines is indeed useful for drug screening
purposes.
Kinetic Parameters of MPP+ and 3TC
Uptake Mediated by hOCT1 SNPs
HEK293 cells stably expressing the polymorphic variants
R61C, C88R, S189L, M420del, and G465R were used for the
characterization of MPP+ and 3TC uptake kinetics. These
determinations were performed at 1 s for MPP+ and at 15 s for
3TC. Under these conditions, non-hOCT1-relatedMPP+ uptake
is negligible (Supplementary Figure 2). Results are shown in
Figure 1.
Km and Vmax values were calculated by fitting the
experimental data to a Michaelis Menten curve. In case of the
C88R and G465R variants, data could not be fitted because
uptake rates for both substrates mediated by these variants
were too low. Km values for MPP+ were similar to the
wild type transporter for all tested variants. However, for
3TC, the S189L Km value was significantly higher (p < 0.01)
than for the wild type transporter. Although Vmax values
for all drugs were significantly decreased in all polymorphic
variants, they were particularly much lower when 3TC was the
assayed substrate than when using the hOCT1 substrate model
MPP+, thereby anticipating differential interaction properties
in a substrate-dependent manner. Transport efficiency was
calculated by dividing Vmax by Km values. Ratios above 1 were
considered to be associated with adequate transporter efficacy.
Nevertheless, measurements were performed on cell clones stably
overexpressing these transporter variants, which contributes to
increase transport efficacy. In any case, based upon this premise,
it can be concluded that even though MPP+ transport efficiency
was significantly reduced for the R61C transporter (3.4-fold,
p < 0.01) this variant could still be considered an effective
transporter if expressed at levels high enough as to warrant
efficient substrate translocation. In fact, it seems that none of the
assayed hOCT1 polymorphic transporters showed a significant
impairment in MPP+ uptake, despite a general tendency to
decreased efficacy, being transport efficiency values very high
in all tested cell lines. This was completely different when
the same panel of transporter variants were assayed for 3TC
transportability. Transport efficiency for 3TC was comparatively
TABLE 2 | hOCT1 studied SNPs defined by rs number and amino acid (AA) change.
dbSNP AA change Allele Freq Caucasians MPP+ uptake 3TC uptake Metformin uptake 5 min3
(%)1 1 min 1 min
rs12208357 R61C 0.7 75 40 5
rs55918055 C88R 0.622 10 25 n.d
rs683369 F160L 0.65 100 100 100
rs34104736 S189L 0.5 80 50 25
rs2282143 P341L 0 100 85 100
rs34130495 G401S 1.1 10 25 10
rs628031 M408V 59.8 100 100 100
rs35167514 M420del 18.5 80 50 30
rs34059508 G465R 4 10 20 5
The different compounds uptake is expressed as percentage of hOCT1 wild type uptake. MPP+ and 3TC uptake measurements were performed in transiently transfected HeLa cells.
Those polymorphic variants highlighted in gray were chosen for being further characterized and stable HEK293 cells expressing them were generated. 1 (Shu et al., 2003). 2 (Kerb et al.,
2002). 3(Shu et al., 2007).
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FIGURE 1 | Kinetic studies for 3TC and MPP+. Kinetic studies were performed in HEK293 stably expressing hOCT1 wild type or one of the polymorphic variants.
For MPP+ the uptake was measured at 1 s and for 3TC at 15 s to enhance the sensibility. Kinetic parameters shown in the table were calculated fitting data to a
Michaelis Menten curve. Unpaired t-Student test was performed. (**p < 0.01; ***p < 0.001).
much lower than for the hOCT1 model substrate MPP+,
albeit still being consistent with hOCT1 being a suitable 3TC
transporter as previously determined (Minuesa et al., 2009).
However, in this case, all tested polymorphic hOCT1 proteins
showed a dramatic impairment in transport efficiency when
compared to the wild type transporter, being the Vmax/Km ratio
close to or even lower than 1 (showing a 11-fold decrease for
R61C and >4-fold for S189L and M420del, all p < 0.01).
Oligomerization of hOCT1 and Two of Its
Polymorphic Variants Located at the Large
Extracellular Loop
Two of the studied polymorphic variants implicate cysteines
(R61C and C88R) located at the large extracellular loop of
the hOCT1 protein. They either add a new cysteine (R61C)
within the loop or substitute an already existing one by arginine
(C88R). Cysteines located at the extracellular loop of human
Organic Cation Transporters have recently been implicated in the
oligomerization and proper trafficking to the plasma membrane
of hOCT2 (Brast et al., 2012). Oligomerization studies were
performed to determine if these polymorphic variants affecting
cysteines at the extracellular loop could still form oligomers.
For this purpose, His-tagged and FLAG-tagged hOCT1 WT
and the polymorphic variants of interest were incubated with
Ni2+-NTA-agarose beads able to bind His-tagged proteins, as
previously reported for rOCT1 (Keller et al., 2011). FLAG-
tagged proteins bound to His-tagged proteins in all cases,
except for the FLAG-rOAT1 which could not oligomerize with
His-rOCT1. This was used as a negative control of the assay
(Figure 2). Data were consistent with the view that both R61C
and C88R variants were still able to oligomerize, although it
Frontiers in Pharmacology | www.frontiersin.org 5 June 2016 | Volume 7 | Article 175
Arimany-Nardi et al. Antiviral Interaction with hOCT1 Variants
FIGURE 2 | Oligomerization of polymorphic variants located at the extracellular loop. The samples were diluted with 200 µL of Tris buffer containing 1%
CHAPs and 10 mM imidazole (lanes 1). After 1 h incubation at 4◦C, Ni2+-NTA-agarose beads were added, the suspension was incubated for 1 h and centrifuged.
Supernatants were collected (lanes 2). The beads were washed five times with 1 mL of buffer and pelleted (supernatants lanes 3). His-tagged proteins were eluted by
incubating the beads with 400 µl of buffer containing 1% CHAPS and 100 mM imidazole (supernatant lanes 4). Proteins were separated by SDS-PAGE, transferred to
a blotting membrane, and stained with an antibody against the FLAG tag. The experiment was performed three independent times. The mean ± S.D. are shown in the
table.
does not necessarily mean that oligomers are inserted into the
plasma membrane as efficiently as for the wild type proteins.
These observations also suggest that the cysteine at the 88
position is not essential for the correct oligomerization of the
transporter.
Drug-Drug Interactions in hOCT1
Polymorphic Variants
Management of HIV-1 infection usually includes the
combination of multiple antiretroviral drugs. Besides 3TC,
other Nucleoside Reverse Transcriptase Inhibitors (NRTI)
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antiviral drugs, such as ABC, have been shown to interact
with hOCT1, despite not being translocated by the transporter
(Minuesa et al., 2009). In addition, in the case of metformin,
the polymorphic variant M420del has been determined
to be more sensitive to drug-drug interactions than the
wild type transporter (Ahlin et al., 2011). These facts
raised the question of what would be the pharmacological
impact of these variants on drug-drug interactions of clinical
relevance.
To address this issue, different antiretroviral drugs which are
often co-administrated with 3TC were selected. The tested drugs
were ABC, AZT, FTC, and TDF from the Nucleoside Reverse
Transcriptase Inhibitors (NRTIs) group; EFV from the Non-
Nucleoside Reverse Transcriptase Inhibitor (NNRTI) group and
RAL form the HIV-1 Integrase Inhibitors group. A fixed high
concentration (500 µM) for each interacting drug and 10 µM,
2 µCi of [3H]3TC as substrate were initially used to perform a
cis-inhibition profiling of the wild type hOCT1 transporter, stably
expressed in HEK293 cells, as mentioned above. We were aware
that this concentrations was far beyond the reported maximum
concentrations (Cmax) for all these drugs, but we designed this
study simply as a preliminary step to identify putative interacting
candidates. Results shown in Figure 3, demonstrate that ABC,
EFV, and RAL inhibited hOCT1-mediated 3TC uptake. These
drugs were selected for further studies along with AZT, one of the
drugs which is more often co-administrated with 3TC. The fact
that AZT could not inhibit the wild type hOCT1 does not rule out
the possibility of this drug showing altered interactions with the
polymorphic transporters. Cmax representative concentrations
(Table 3, Jilek et al., 2012) were also used for further cis-inhibition
studies. Under those conditions, only EFV could significantly
inhibit 3TC uptake mediated by the wild type transporter
(Figure 3).
The functional impact on drug-drug interactions of
polymorphic variants relevant to the clinics was studied
using additional cis-inhibition assays. For this purpose, HEK293
cells stably expressing either the wild type hOCT1 or the
selected variants were used. As mentioned above, only those
variants for which Km and Vmax values could be calculated
were chosen for drug-drug interaction assays. As shown in
Figure 4, significant differences were observed for each assessed
interaction (ABC, AZT, EFV, and RAL, each tested against 3TC
uptake) among polymorphic variants. ABC, despite not being
able to significantly inhibit the wild type hOCT1-mediated
uptake of 3TC could significantly inhibit its uptake mediated by
the polymorphic variants R61C and M420del. AZT could only
significantly inhibit the uptake mediated by the polymorphic
variant M420del. EFV, as mentioned before, was able to inhibit
3TC transport mediated by the wild type transporter, although
it could not block R61C function. Interestingly, EFV was also
more capable to inhibit 3TC uptake mediated by the S189L
and M420del variants than that associated with the wild type
transporter. Interestingly, RAL co-administration with 3TC did
not reduce but even increased 3TC uptake mediated by the
polymorphic variant R61C whereas it could slightly decrease its
transport when this was mediated by the M420del polymorphic
variant (Figure 4).
FIGURE 3 | 3TC uptake inhibited by other antiretroviral drugs.
Percentage of inhibition of 500 µM antiretroviral drugs (up) or Cmax
concentration (down) to the uptake of 10 µM, 2 µCi of 3TC mediated by
hOCT1. The uptake was measured at 15 s. The graph shows the mean ±
S.E.M of three independent experiments. (*p < 0.05; **p < 0.01; ***p < 0.001).
TABLE 3 | Cmax (nature med 2012 Jilek) and concentration used of the
antiretroviral drugs for the cis-inhibition studies.
Drug Class Cmax (µM) Used concentration (µM)
3TC NRTI 15, 29 10
ABC NRTI 13, 48 13
AZT NRTI 4, 45 4
EFV NNRTI 12, 97 13
RAL InST1 4, 50 4
DISCUSSION
This study demonstrates that selected hOCT1 polymorphic
proteins, some of them showing relatively high allelic frequency
in humans, may show variable efficacy for drug uptake, in this
case for 3TC translocation, but also variable interaction with
co-administered antivirals known to be high affinity inhibitors
of hOCT1-mediated 3TC uptake (Minuesa et al., 2009).
All interacting drugs were assayed at Cmax concentrations.
Although this may not necessarily reflect free unbound
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FIGURE 4 | Cis-inhibition studies of 3TC with other antiretroviral drugs in hOCT1 polymorphic variants. 3TC (10 µM, 2 µCi) uptake was inhibited with a
dose close to the Cmax value of other antiretroviral drugs in HEK293 stably expressing the WT transporter or one of its polymorphic variants. Graphs show the mean
± S.E.M of three to four single experiments. (*p < 0.05; **p < 0.01; ***p < 0.001).
circulating drug levels, they are closer to the clinics, thereby
anticipating that interactions may potentially modulate 3TC
pharmacokinetics and pharmacodynamics. This issue will
require further clinical pharmacological approaches which are
beyond the scope of this contribution. In this particular case we
focused on the molecular variants of hOCT1 and their drug-
interaction properties, thereby providing novel basic knowledge
to the HIV-1 infection therapeutics field. However, the clinical
impact of hOCT1 genetic heterogeneity in humans has been
studied for several drugs so far, being metformin a paradigm
among them. The three variants here studied in more detail,
R61C, S189L, and M420del, have been reported to determine
decreased metformin uptake. For the two latter at least, kinetic
analyses revealed that low activity was mostly accounted by
decreased Vmax values, without significant Km changes (Shu
et al., 2007). In this report, although Km values were significantly
increased (nearly 50% vs. the wild type transporter) for the
S189L variant when looking for 3TC transportability, it is
similarly evident that the most striking alteration in 3TC uptake
kinetics was associated with decreased Vmax values. Overall,
this resulted in a dramatic loss of transport efficacy (Vmax/Km
ratio). The possibility that these alterations would be a mere
consequence of altered transporter expression levels is unlikely
because kinetic changes are not of the same magnitude than
the ones found for the hOCT model substrate MPP+. In this
regard transport efficacy is not even significantly impaired
when analyzing the performance of the S189L and M420del
variants using MPP+ as substrate, which is not the case
when determining 3TC uptake kinetic parameters. Moreover,
as discussed below, altered drug-drug interaction properties
with hOCT1 polymorphic variants are totally independent on
transporter expression levels but, instead, rely upon inherent
transporter translocation mechanisms. More importantly, the
probable link between the occurrence of these three variants,
R61C, S189L, and M420del and altered drug pharmacokinetics
has also been studied in humans receiving metformin. In
all cases, individuals bearing these polymorphic transporters
showed increased Area Under the Curve (AUC) and Cmax
values for this drug (Shu et al., 2008), thereby suggesting that
there might be a direct link between altered function of hOCT1
proteins and in vivo metformin handling. Moreover, although
still controversial, the occurrence of these variants has also
been reported to associate with high metformin renal clearance
(Tzvetkov et al., 2009). Thus, it is highly likely that similar effects
could be anticipated for other hOCT1 substrates, such as 3TC.
Overall, these observations are consistent with the known tissue
distribution of hOCT1 in humans. hOCT1 is expressed at the
sinusoidal (basolateral) membrane of hepatocytes (Nies et al.,
2009) and at the apical and sub-apical domains of proximal
and distal tubules in human kidney (Tzvetkov et al., 2009).
It is also apically located in small intestine, and in general,
is present in many other epithelia (Koepsell et al., 2007; Han
et al., 2013). In summary, as briefly introduced above, hOCT1
localization in the main epithelial barriers of the body makes
Frontiers in Pharmacology | www.frontiersin.org 8 June 2016 | Volume 7 | Article 175
Arimany-Nardi et al. Antiviral Interaction with hOCT1 Variants
it a suitable candidate to modulate the pharmacokinetics of
hOCT1 substrates. Not only genetic heterogeneity may apply to
pharmacologically relevant epithelial barriers but also, to target
cells. In this regard, hOCT1 in the sinusoidal membrane of
hepatocytes can contribute to metformin effects in antidiabetic
therapy, as long as the hepatocyte is by itself a cell target for
treatment. It may also determine the antiviral efficacy of 3TC
itself, in HBV therapy. Moreover, despite some controversy still
exists about whether hOCT1 is a sorafenib transporter or not, it
has recently been shown that sorafenib uptake and cytotoxicity
might be affected by hOCT1 gene heterogeneity in humans
(Herraez et al., 2013). Bendamustine, a drug currently used in
front line treatment of Chronic Lymphocytic Leukemia (CLL)
also appears to be a hOCT1 substrate and genetic heterogeneity
in CLL patients appears to account for a subset of cases
with altered drug sensitivity (Arimany-Nardi et al., 2015b). But
besides gene heterogeneity, the abundance of the transporter
itself might eventually contribute to drug action. Thus, even
though particular somatic hOCT1 mutations have been recently
identified in hepatocarcinomas (Herraez et al., 2013), decreased
expression of this drug transporter has also been reported when
compared to adjacent non-tumor tissue (Martinez-Becerra et al.,
2012). In this regard, it should be noted that high variability
in hOCT1 expression has also been reported in healthy livers
among individuals (Nies et al., 2009). hOCT1 is also known to
be expressed in most immune system cells, including a major
target in AIDS therapy, CD4+ T cells (Minuesa et al., 2008; Jung
et al., 2013). Moreover, hOCT1 expression also appears to be up-
regulated when cells are stimulated by cytokines, mimicking what
could be happening in the HIV-1 infection context (Minuesa
et al., 2008). Overall this highlights the possibility of drug
handling being determined by both, transporter abundance and
genetic heterogeneity.
Although hOCT1 is a highly polymorphic transporter,
which has been quite well studied for a decent amount of
substrates so far, there is still little information about how genetic
heterogeneity can affect drug-drug interactions. This issue
might be relevant in therapeutic regimes aimed at treating HIV-1
infection and, probably other viral infectious diseases. 3TC-based
antiretroviral regimens have beenwidely used inHIV-1 therapies.
The drug was first co-formulated with AZT (Combivir R©), and
subsequently with ABC (Kivexa R©). Fix-dose combinations
of 3TC have been also manufactured with AZT+ABC
(Trizivir R©), and more recently with ABC+dolutegravir
(Triumeg R©). In 2009, the FDA granted approval for generic
formulations of 3TC. In this regard, the fact that R61C and
M420del variants showed a more variable profile of drug-
drug interactions when compared to the wild-type protein
highlights the importance that these polymorphisms can have
in drug bioavailability and action when administered in drug
combinations.
A major issue in the field would be how to predict this type
of interactions based upon structure-function knowledge of the
hOCT1 protein. This could be useful for new drug development
and could also be eventually extended to other members of
the SLC22 gene family, sharing high homology with hOCT1.
Nevertheless, structural knowledge is still poor. Moreover, an
additional element of complexity is added to this problem, this
is the fact that the fully functional transporter is built up as
an oligomer and the functional impact of the variants on the
monomers crosstalk and, in particular of those polymorphisms
located in the first extracellular loop of the protein, are very
difficult to predict.
In summary, this study provides novel insights on how 3TC
interacts with hOCT1 polymorphic proteins. It also addresses
the very interesting question of how genetic heterogeneity
would determine variable drug-drug interactions, an issue of
particular relevance in AIDS treatment. It should be noticed that
some polymorphic variants showing great functional complexity,
such as M420del, are present in humans with high allelic
frequency and thus, it is likely to play a major impact in drug
pharmacokinetics under combined therapies. Overall, this study
highlights the need for establishing functional assays aiming at
anticipating drug-drug interactions at the early stages of drug
development.
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